Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-301?
TN-301 is a small molecule commercialized by Tenaya Therapeutics, with a leading Phase I program in Diastolic Heart Failure (HFpEF)....
Data Insights
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-301?
TN-301 is a small molecule commercialized by Tenaya Therapeutics, with a leading Phase I program in Diastolic Heart Failure (HFpEF)....